Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia | Zendy

Sweeney | Zendy; William L. Irving | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia

Author(s) -

Sweeney,

William L. Irving

Publication year - 2012

Publication title -

journal of pain research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.888

H-Index - 49

ISSN - 1178-7090

DOI - 10.2147/jpr.s32562

Subject(s) - medicine , placebo , tolerability , postherpetic neuralgia , somnolence , adverse effect , anesthesia , gabapentin , discontinuation , neuropathic pain , alternative medicine , pathology

An immediate-release formulation of gabapentin is approved for treatment of postherpetic neuralgia (PHN). This formulation, however, requires multiple daily dosing, usually three times per day, and is associated with a high incidence of somnolence and dizziness. We assessed the tolerability and safety of a once-daily gastroretentive formulation of gabapentin (G-GR) in phase 3 clinical trials in patients with PHN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research